135
Participants
Start Date
October 31, 2022
Primary Completion Date
September 30, 2025
Study Completion Date
December 15, 2025
JNT-517 Suspension
JNT-517 in on-site compounded suspension
Placebo Suspension
On-site compounded placebo suspension
JNT-517 Tablet
JNT-517 tablets, 25 mg and 75 mg
Placebo Tablet
Matching film-coated placebo tablet
Westmead Hospital, Westmead
Nucleus Network Melbourne, Melbourne
Mater Misericordia Ltd, South Brisbane
Royal Adelaide Hospital, Adelaide
UPMC Children's Hospital of Pittsburgh, Pittsburgh
Children's Hospital of Philadelphia, Philadelphia
Rare Disease Research, Atlanta
University of Florida College of Medicine, Gainesville
University of South Florida, Tampa
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
University of Nebraska Medical Center, Omaha
UT Southwestern Medical Center, Dallas
University of Texas Health Science Center at Houston, Houston
Utah Health - The University of Utah Hospital, Salt Lake City
Oregon Health & Sciences University, Portland
Otsuka Pharmaceutical Development & Commercialization, Inc.
INDUSTRY